Pharvaris (PHVS) Chief Medical Officer Peng Lu Sells 300 Shares

On June 18, 2026, Peng Lu, the Chief Medical Officer of PHVS, sold 300 shares of the company. This transaction wasn't part of a pre-arranged plan. The sale occurred as PHVS shares traded around $33.

Insider Buying and Selling at Pharvaris N.V.

Peng Lu, PHVS's Chief Medical Officer, was active on June 18, 2026, selling 300 shares without a pre-planned sale. Additionally, on June 15, 2026, Chief Executive Officer Berndt Modig sold 2,291 shares at an average price of $31.07 as part of a planned transaction.

Other Institutional Activity in PHVS

General Atlantic, L.P. holds a substantial stake in PHVS, with 8,031,252 shares valued at approximately $226.9 million, maintaining its position with no change. FMR LLC trimmed its holdings by 114,686 shares, ending with 6,284,472 shares worth about $177.5 million, marking a 1.8% decrease. Other major holders like Foresite Capital Management IV, LLC, Venbio Partners LLC, and Viking Global Investors LP kept their positions steady.

Pharvaris N.V. Stock Down 9.3%

Shares of PHVS traded near $33 on Wednesday. The stock has shown volatility, with a 52-week range yet unspecified here. Despite this, the market remains optimistic about its potential, as reflected in the interest from institutional investors.

Analysts Set New Price Targets

Analysts are bullish on PHVS, with Citizens maintaining a 'buy' rating and a $74 price target as of May 13, 2026. Wolfe Research initiated coverage with a 'buy' rating and a $42 target on April 9, 2026. Similarly, Wedbush and RBC Capital have maintained 'buy' ratings with targets of $42 and $51, respectively.

Bottom Line

Insider transactions like Peng Lu's sale provide insights into executive sentiment but don't necessarily predict stock performance. Investors often track these moves for potential signals. Analyst support remains strong for PHVS, with several firms maintaining 'buy' ratings and optimistic targets, suggesting continued confidence in the company's prospects.